| 000 | 01461 a2200409 4500 | ||
|---|---|---|---|
| 005 | 20250513071722.0 | ||
| 264 | 0 | _c19940308 | |
| 008 | 199403s 0 0 eng d | ||
| 022 | _a0959-8049 | ||
| 024 | 7 |
_a10.1016/0959-8049(93)90044-g _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aButer, J | |
| 245 | 0 | 0 |
_aPhase I/II study of low-dose intravenous OKT3 and subcutaneous interleukin-2 in metastatic cancer. _h[electronic resource] |
| 260 |
_bEuropean journal of cancer (Oxford, England : 1990) _c1993 |
||
| 300 |
_a2108-13 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aCarcinoma, Renal Cell _xdrug therapy |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aInfusions, Intravenous |
| 650 | 0 | 4 | _aInjections, Subcutaneous |
| 650 | 0 | 4 |
_aInterleukin-2 _xadministration & dosage |
| 650 | 0 | 4 |
_aKidney Neoplasms _xpathology |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aMelanoma _xdrug therapy |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aMuromonab-CD3 _xadministration & dosage |
| 700 | 1 | _aJanssen, R A | |
| 700 | 1 | _aMartens, A | |
| 700 | 1 | _aSleijfer, D T | |
| 700 | 1 | _ade Leij, L | |
| 700 | 1 | _aMulder, N H | |
| 773 | 0 |
_tEuropean journal of cancer (Oxford, England : 1990) _gvol. 29A _gno. 15 _gp. 2108-13 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/0959-8049(93)90044-g _zAvailable from publisher's website |
| 999 |
_c8296929 _d8296929 |
||